Cancer treatment and research communicationsHumansPhosphoinositide-3 Kinase InhibitorsNeoplasmsAntineoplastic AgentsProtein Kinase Inhibitors
PI3K inhibitors: Efficacy in diverse cancer forms.
Ehsan Kianfar, Alaa M Alrudainy, Ayoob Radhi Al-Zaalan, Wesam R Kadhum, Amar Yasser Jassim
Published: 202510.1016/j.ctarc.2025.101028
Abstract
One promising target for creating new anticancer medications is phosphatidyl-inositol-3-kinase (PI3K). Many human malignancies, including brain, colon, endometrial, breast, and prostate cancers, have been linked to PI3K dysregulation. The genes for P…
Preview only. Read the full abstract at the source